Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Alvotech ( (ALVO) ) is now available.
Alvotech, a Luxembourg-based biosimilars specialist founded by Robert Wessman, has built a global commercial footprint via strategic partnerships spanning the U.S., Europe, Japan, China and other key markets. Its portfolio includes biosimilars to Humira, Stelara, Simponi, Eylea and Prolia/Xgeva, supporting its ambition to be a leading cost-efficient biologics provider.
On March 18, 2026, Alvotech reported Q4 and full-year 2025 results, highlighting 13% quarterly and 21% annual revenue growth to $173 million and $593 million respectively, and stronger profitability with adjusted EBITDA of $137 million. The company secured multiple biosimilar approvals in the UK, EEA and Japan, expanded via acquisitions in Sweden and Switzerland, listed on Nasdaq Stockholm, refreshed its leadership with a new CEO and CFO, and signaled progress in resolving FDA observations at its Reykjavik plant, underlining a broader strategic push to scale its global biosimilars platform.
In Q4 2025, Alvotech’s gross margins reached 66% and adjusted EBITDA hit $69 million, supported by product launches and an expanding pipeline including AVT05 and AVT03 approvals and EMA review of AVT23. Management emphasized that capital raises of nearly $300 million, a broadened investor base and new commercialization deals with Sandoz in Canada, Australia and New Zealand position the group to deepen its market penetration and strengthen operational resilience.
Operationally, Alvotech now counts five approved, on-market biosimilars and an industry-leading pipeline of 30 candidates in development, enabling commercial reach into about 90 countries. Leadership changes, including the appointment of Lisa Graver as CEO and other senior executive moves, consolidate decision-making in Iceland as the company prepares for further regulatory milestones and additional launches in Europe, the UK and Japan.
Alvotech also published its 2026 financial calendar alongside the March 18, 2026 disclosure of its earnings and business update. The schedule, running from May 2026 through March 2027, sets out quarterly reporting and earnings calls, giving investors clearer visibility on forthcoming disclosures as the company executes its growth agenda in the biosimilars market.
The most recent analyst rating on (ALVO) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.
Alvotech’s overall stock score is driven by financial instability, bearish technical indicators, and regulatory challenges impacting short-term outlook. While strategic investments and historical growth are positives, significant risks remain.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech is a biotechnology company focused exclusively on developing and manufacturing biosimilar medicines for patients worldwide. It offers high-quality, cost-effective alternatives to branded biologics through a fully integrated platform, with five biosimilars already approved and marketed globally and a pipeline targeting autoimmune, eye, bone, respiratory and cancer indications.
Average Trading Volume: 502,767
Technical Sentiment Signal: Sell
Current Market Cap: $1.26B
See more data about ALVO stock on TipRanks’ Stock Analysis page.